Biotech Startups

Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.

1 investor

Panacea-ml provides clinical development data analytics to pharmaceutical companies and contract research organizations, helping them design and conduct clinical trials more efficiently by identifying optimal trial participants and predicting adverse outcomes.

1 investor

1 investor

Pando develops enzyme design and optimization using machine learning to accelerate the design-build-test-learn cycle for biotechnology applications.

1 investor

Pangea Biomed develops computational and data-driven platforms to advance precision oncology, helping researchers and clinicians select optimal cancer treatments and understand tumor biology. The company serves drug development teams, oncologists, and cancer centers globally.

1 investor

Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.

1 investor

panluminate develops instruments and processes for whole-brain connectomic mapping at scale, using its pan-ExM imaging technique to capture both neural wiring and molecular state simultaneously at 15nm resolution. It serves neuroscience research institutions with products and services that combine high-resolution microscopy and AI-based segmentation of brain circuitry.

1 investor

Pannex Therapeutics is developing Pannexin 1 (Panx1) channel blockers, a drug platform targeting pathological ATP release that drives neuroinflammation and immune dysregulation. Its therapeutics address unmet medical needs in neurology and oncology.

1 investor

Pano Therapeutics develops small-molecule drug candidates targeting mitochondrial dysfunction, with a lead program in Fragile X Syndrome and neurodevelopmental disorders. The company's approach builds on metformin's mechanisms and is designed to serve patients with syndromic neurodevelopmental disorders.

1 investor

1 investor

Panoptive provides a software platform that continuously monitors clinical trials by converting monitoring reports and electronic data capture (EDC) data into structured findings, documented decisions, and audit-ready oversight records. The platform serves sponsors and clinical operations teams conducting regulated trials and helps organizations surface quality issues early while maintaining inspection-ready documentation.

1 investor

PanTheryx is a health and nutrition company that develops and commercializes consumer health supplements for the human health and wellness market, including products for digestive support and dietary needs.

1 investor

Panthura develops non-viral DNA delivery technology for sustained therapeutic effects in specific tissues, with potential for repeated administration. The company is advancing its platform through preclinical and clinical development stages.

1 investor

Paques develops ANAMMOX®, a biological nitrogen removal system that converts ammonium and nitrite into nitrogen gas, serving municipal and industrial wastewater treatment facilities. The company's patented technology achieves significant operational cost savings and CO2 emission reductions compared to traditional nitrogen removal methods.

1 investor

Paques Biomaterials produces biodegradable PHA polymers from renewable resources and circular feedstocks using proprietary bacterial fermentation technology. The company operates demonstration and pilot facilities in the Netherlands to produce its branded Caleyda material for diverse industrial applications.

1 investor

1 investor

Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process. It works with providers and sponsors to increase patient enrollment and expand patient access to clinical trials.

1 investor

Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.

1 investor

Parallel Health offers a skincare product line addressing aging through microbiome science, including peptide creams and cleansers designed to target the hallmarks of skin aging.

1 investor

Paralos is developing a modular M13 phage drug delivery platform that creates phage-drug conjugates to concentrate therapeutic payloads at specific targets. The platform pairs programmable target binding with payload presentation to localize drug exposure and engineer delivery around the therapeutic window.

1 investor

1 investor

Parasma develops algorithms and infrastructure to train living neural systems for computation, aiming to make advanced AI far more energy-efficient and accessible by leveraging biological neurons as programmable compute. The company serves organizations seeking to reduce the energy footprint and hardware costs of AI systems.

1 investor

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

1 investor

Parima is developing technology to reinvent how animal proteins are produced, working at the cellular level to make animal production more efficient and sustainable. It positions itself in the biotech and cellular/cultivated protein space.

1 investor